Physician profile
Anna Renkiewicz
NPI 1770888778
$1,762.08
in general payments reported to CMS, 2019-2025
13 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $162 · 2021: $202 · 2022: $149 · 2023: $450 · 2024: $250 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $991.35 | 2019-2025 | Yeztugo, Epclusa |
| Viiv Healthcare Company | $130.26 | 2019-2025 | Dovato, Apretude |
| Glaxosmithkline, LLC. | $122.46 | 2019-2023 | Bexsero, Pediarix |
| Abbvie INC. | $116.82 | 2021-2023 | |
| Alkermes, INC. | $82.04 | 2019-2024 | Vivitrol, Vivitrol |
| Novo Nordisk INC | $79.00 | 2023-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $66.61 | 2019-2024 | Delstrigo |
| Theratechnologies INC. | $57.78 | 2019-2022 | |
| Sanofi Pasteur INC. | $38.85 | 2019 | |
| Amgen INC. | $20.73 | 2025 | Repatha |
| Phadia US INC. | $19.12 | 2019 | |
| Allergan, INC. | $18.65 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $18.41 | 2023 | Abilify Asimtufii, Abilify Maintena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Renkiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.